Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights GlobeNewswire August 05, 2025 – First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in development for glioblastoma – BOSTON, Aug. 05, 2025 […]

Bitfarms Announces Partnership with T5 Data Centers to Advance HPC/AI Development at Panther Creek Campus GlobeNewswire August 05, 2025 TORONTO, Ontario and NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) — Bitfarms Ltd. (Nasdaq/TSX: BITF) (the “Company”), a global energy and compute infrastructure company, today announced its partnership with T5 Data Centers, LLC (“T5”) to advance

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update GlobeNewswire August 05, 2025 FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical synergistic benefit of FHD-909 in combination with pembrolizumab and KRAS

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference GlobeNewswire August 05, 2025 SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the

Xtract One Chosen by Volusia County Schools to Advance School Safety Xtract One Gateway Deployment to Improve School Security Screenings with Non-intrusive Technology for the 2025-2026 School Year GlobeNewswire August 05, 2025 TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced its Xtract

Iterum Therapeutics Reports Second Quarter 2025 Financial Results GlobeNewswire August 05, 2025 –– Launch of ORLYNVAHTM Expected August 2025– –-Cash Runway into 2026– –Company to host conference call today at 8:30amET– DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV

Forsys Announces Commencement of Expansion Drill Program at Namibplaas GlobeNewswire August 05, 2025 TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Forsys Metals Corp. (TSX: FSY) (FSE: F2T) (NSX: FSY) (“Forsys” or the “Company”) Forsys is pleased to announce the commencement of a drill program comprising 64 drill holes at its Namibplaas uranium property (“Namibplaas” or

Envision Pharma Group appoints Tom Langan as Chief Executive Officer GlobeNewswire August 05, 2025 Envision Pharma Group appoints Tom Langan as Chief Executive Officer Leading industry executive with 30 years' of experience providing technology-enabled solutions to life sciences companies Fairfield, Connecticut, USA, and Horsham, United Kingdom – August 5, 2025 – Envision Pharma Group, a

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update GlobeNewswire August 05, 2025 Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026 Other clinical trials

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update GlobeNewswire August 05, 2025 AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development ACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson's disease produced strong immunogenicity and